ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 2165 • ACR Convergence 2025

    Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study

    Rachel Guess1, Megan Curran2, Lisa Zickuhr3 and Rachel Moquin1, 1Washington University School of Medicine, St. Louis, MO, 2University of Colorado | Children's Hospital Colorado, Aurora, CO, 3Washington University/B-JH/SLCH Consortium, St. Louis, MO

    Background/Purpose: Juvenile scleroderma (JS) is an autoimmune disease that can cause skin sclerosis leading to deformity, disability, and early mortality especially with delayed diagnosis. A…
  • Abstract Number: 1582 • ACR Convergence 2025

    Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)

    Marissa Savoie1, Monica Harding2, John VanBuren2, Shervin Assassi3, Elana Bernstein4, Lorinda Chung5, Luke Evnin6, Tracy Frech7, Jessica Gordon1, Faye Hant8, Laura Hummers9, Dinesh Khanna10, Kimberly Lakin1, Dorota Lebiedz-Odrobina2, Yiming Luo4, Ashima Makol11, Maureen Mayes12, Zsuzsanna McMahan13, Jerry Molitor14, Duncan Moore15, Carrie Richardson16, Nora Sandorfi17, Ami Shah9, Ankoor Shah18, Brian Skaug19, Virginia Steen20, Elizabeth Volkmann21, Carleigh Zahn10 and Flavia Castelino22, 1Hospital for Special Surgery, New York, NY, 2University of Utah, Salt Lake City, UT, 3Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 4Columbia University, New York, NY, 5Stanford University, Stanford, CA, 6Scleroderma Research Foundation, Brisbane, CA, 7Vanderbilt University Medical Center, Nashville, TN, 8Medical University of South Carolina, Charleston, SC, 9Johns Hopkins Rheumatology, Baltimore, MD, 10University of Michigan, Ann Arbor, MI, 11Mayo Clinic, Rochester, MN, 12UT Health Houston Division of Rheumatology, Houston, TX, 13UT Health Houston, Houston, TX, 14University of Minnesota, Minneapolis, MN, 15Northwestern Memorial Hospital, Chicago, IL, 16Northwestern University, Chicago, IL, 17University of Pennsylvania, Philadelphia, PA, 18Duke University, Durham, NC, 19UTHealth Houston Division of Rheumatology, Houston, TX, 20Georgetown University School of Medicine, Washington, DC, 21Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, 22Massachusetts General Hospital, Boston, MA

    Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…
  • Abstract Number: 0965 • ACR Convergence 2025

    Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis

    Kamal Saba1, Rong Huang2, Priyanka Verma1, M Asif Amin1 and John Varga1, 1University of Michigan, Ann Arbor, MI, 2Purdue University, West Lafayette, IN

    Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive fibrosis driven by sustained fibroblast activation and senescence. Nicotinamide N-methyltransferase (NNMT), a SAM-dependent enzyme, is upregulated in…
  • Abstract Number: 0681 • ACR Convergence 2025

    Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis

    Aïcha Kante1, Sandra Mghaieth2, bertrand Dunogue3, Alice berezne3, Cloé Comarmond1, Marie-Pierre Revel2, Guillaume Chassagnon2, Luc Mouthon3 and Benjamin Chaigne3, 1Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U942, Paris, France, 2Radiology Department, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 3Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France

    Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease that can manifest as widespread skin and visceral fibrosis, potentially affecting major organs including the heart.…
  • Abstract Number: 2047 • ACR Convergence 2025

    Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades

    Sambhawana Bhandari1, Derek E. Byers1 and Deepali Sen2, 1Washington University in St. Louis School of Medicine, St. Louis, 2Washington University in St Louis, Chesterfield, MO

    Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
  • Abstract Number: 1583 • ACR Convergence 2025

    Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021

    Patompong Ungprasert1 and Paul Kroner2, 1Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH, 2Riverside Health System, Newport News, VA

    Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…
  • Abstract Number: 0966 • ACR Convergence 2025

    Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset

    kristina clark1, Xu Shiwen2, Xue Li2, Voon H. Ong3 and Christopher Denton4, 1Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, 2University College London, London, United Kingdom, 3Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 4University College London, UK, London, United Kingdom

    Background/Purpose: The cell surface protein GPR68 (ovarian cancer G protein-coupled receptor 1, OGR1) is a proton-sensing G-protein-coupled receptor (GPCR) that responds to extracellular acidity and…
  • Abstract Number: 0677 • ACR Convergence 2025

    Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.

    Jessica Fairley1, Elizabeth Paratz2, Dylan Hansen3, Susanna Proudman4, Joanne Sahhar5, Gene-Siew Ngian6, Diane Apostolopoulos6, Jennifer Walker7, Lauren Host8, Wendy Stevens1, Andre La Gerche2, Mandana Nikpour9 and Laura Ross1, 1The University of Melbourne, Melbourne, Victoria, Australia, 2St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, 3St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, 4The University of Adelaide, Adelaide, Victoria, Australia, 5Monash Health, Melbourne, Victoria, Australia, 6Monash University, Melbourne, Victoria, Australia, 7Flinders University, Adelaide, Victoria, Australia, 8Fiona Stanley Hospital, Perth, Victoria, Australia, 9University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia

    Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
  • Abstract Number: 1969 • ACR Convergence 2025

    Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy

    Genessis Maldonado1, Sowmika Rao1 and Tracy Frech2, 1Vanderbilt University Medical Center, Nashville, 2Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Raynaud’s phenomenon (RP) is a painful and disabling feature of systemic sclerosis (SSc) that significantly impairs quality of life. Tools that integrate subjective symptom…
  • Abstract Number: 1574 • ACR Convergence 2025

    A rise in serum KL-6 levels predicts subsequent progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease

    Keina Yomono1, Suiyuan Huang2, Dinesh Khanna2 and Masataka Kuwana3, 1Nippon Medical School, Bunkyo-ku, Tokyo, Japan, 2University of Michigan, Ann Arbor, MI, 3Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Interstitial lung disease (ILD) is leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Given the high variable clinical course of…
  • Abstract Number: 0959 • ACR Convergence 2025

    Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score

    Bich Na Choi1, Claudia Pedroza2, Brian Skaug3, Maureen Mayes4 and Shervin Assassi5, 1UTHealth Houston Institute for Clinical Research & Learning Health Care, Houston, TX, 2UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4UT Health Houston Division of Rheumatology, Houston, TX, 5Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX

    Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…
  • Abstract Number: 0884 • ACR Convergence 2025

    Risk Score for Early Mortality to stratify for Intensive SSc Therapy

    Ann-Christin Pecher1, Boubaya Marouane2, Oliver Distler3, Vanessa Smith4, Jeska de Vries-Bouwstra5, Radim Bečvář6, Gianluca Moroncini7, David Launay8, Yannick Allanore9, Maria De Santis10, Kamal Solanki11, Carlomaurizio Montecucco12, Luca Idolazzi13, Nihal Fathi14, Przemyslaw Kotyla15, Muriel Elhai16 and Jörg Henes17, 1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Unit of Clinical Research, Paris Seine Saint Denis University, Bobigny, France, Paris, France, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 4Ghent University Hospital, Gent, Belgium, 5Leiden University Medical Center, Leiden, Netherlands, 6Department of Internal Medicine, Charles University,, Prague, Czech Republic, 7Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, 8Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille France, Lille, France, 9Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, 10Humanitas University, Pieve Emanuele, Italy, 11Waikato Hospital, Hamilton, New Zealand, 12Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, Pavia, Italy, 13Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy, Verona, Italy, 14Department of Rheumatology ,Rehabilitation & physical medicine, Assiut University Hospital, Assiut, Egypt, Assiut, Egypt, 15Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland, 16University Hospital zurich, Zürich, Switzerland, 17Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany

    Background/Purpose: Systemic sclerosis (SSc) is a rare disease that often leads to severe complications and premature mortality. Recent advancements in the field have led to…
  • Abstract Number: 1966 • ACR Convergence 2025

    Assessing the Impact of Cutaneous Melanin on Microvascular Oxygenation Measurement in Systemic Sclerosis Using Multispectral Imaging

    Rosie Barnes1, Joanne Manning2, Graham Dinsdale3, Ariane Herrick4, Mark Dickinson5 and Andrea Murray6, 1University of Manchester, Manchester, England, United Kingdom, 2Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, 3Northern Care Alliance, Salford, United Kingdom, 4The University of Manchester, UK, Aberdeen, United Kingdom, 5The University of Manchester, Manchester, 6University of Manchester, Salford, United Kingdom

    Background/Purpose: Microvascular abnormalities, leading to hypoxia, drive the SSc disease process. Accurate measurement of skin oxygenation, both baseline and during ‘stress’/reperfusion (which can be mimicked…
  • Abstract Number: 1570 • ACR Convergence 2025

    Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses

    Francesco Bonomi1, Ilaria Bisconti2, Ilenia Mallia3, Greta Pellegrino4, Gabriele Ciuti5, Gloria Muolo2, Martina Salerno2, Simona Truglia2, Cristiano Barbetta3, Silvia Peretti5, Serena Guiducci6, Valeria Riccieri7 and Silvia Bellando Randone3, 1University Hospital Careggi, Florence, Florence, Toscana, Italy, 2Sapienza University of Rome, Rome, Rome, Italy, 3University of Florence, Florence, Italy, 4Rheumatology Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milano, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, 5University Hospital Careggi, Florence, Italy, 6Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, 7Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy

    Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug that interferes with dendritic cells and monocytes, acidifies endosomes, and modulates toll-like receptors, reducing autoimmune responses and cell…
  • Abstract Number: 0958 • ACR Convergence 2025

    Asynchronous Resolution of Inflammation and Fibrosis in A Prolonged Experimental Model Suggests Distinct Temporal Dynamics And Resolution Mechanisms in Systemic Sclerosis

    Aurore Collet1, Manel Jendoubi2, Thomas Guerrier2, Alexis Largy2, Silvia Speca2, Sylvain Dubucquoi1 and David Launay3, 1Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Institut d’Immunologie, Lille, France, Lille, France, 2Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France, Lille, France, 3Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille France, Lille, France

    Background/Purpose: Systemic sclerosis (SSc) is characterized by tissue fibrosis, which is defined as excessive and irreversible extracellular matrix (ECM) accumulation, leading to organ dysfunction. In…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology